DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

[Endothelin receptor antagonists - their role in pulmonary medicine]

Author(s): Boniface S, Reynaud-Gaubert M

Affiliation(s): Service de Pneumologie, Pole Cardio-vasculaire et thoracique, CHU Sainte Marguerite, Hopital Sainte Marguerite, Marseille. stephanie.boniface@ap-hm.fr

Publication date & source: 2009-12, Rev Mal Respir., 26(10):1075-90.

Publication type: English Abstract; Review

INTRODUCTION: There has been an explosion of interest in the biology of endothelin-1 in endothelium disease's physiopathology and in particular pulmonary arterial hypertension (PAH). This interest led up to the development of endothelin-receptor antagonists (ERA) drugs as major therapy for advanced PAH. STATE OF THE ART: Three active ERA drugs (bosentan, sitaxentan, ambrisentan) are nowadays approved for the treatment of PAH. Several randomised clinical trials have demonstrated their efficacy and safety in such domain. PERSPECTIVES AND CONCLUSION: Besides its vasoconstrictive effect, endothelin-1 (ET-1) plays a pivotal role on cell proliferation and apoptosis. ET-1 is a particularly interesting molecule linking idiopathic pulmonary fibrosis or systemic sclerosis, although preliminary results are still insufficient or controversial to conclude. CONCLUSION: The role of endothelin-1 in the pathogenesis of fibrosis and angiogenesis needs to be clarified and the interest of ERA in the diseases in which such injuries are preponderant might be demonstrated by further clinical trials.

Page last updated: 2010-10-05

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017